Literature DB >> 28785479

Cancer and Heart Failure: Understanding the Intersection.

Carine E Hamo1, Michelle W Bloom1.   

Abstract

Cancer and cardiovascular disease account for nearly half of all deaths in the US. The majority of cancer therapies are known to cause potential cardiac toxicity in some form. Patients with underlying cardiac disease are at a particularly increased risk for worse outcomes following cancer therapy. Most alarming is the potential for heart failure as a result of cancer treatment, which may lead to early disruption or withdrawal of life-saving cancer therapies and can potentially increase cardiovascular mortality. A multi-disciplinary cardio-oncology approach can improve outcomes through early surveillance, prevention and treatment strategies.

Entities:  

Keywords:  Heart failure; biomarkers; cancer; cardiotoxicity; imaging; surveillance

Year:  2017        PMID: 28785479      PMCID: PMC5494160          DOI: 10.15420/cfr.2016:24:2

Source DB:  PubMed          Journal:  Card Fail Rev        ISSN: 2057-7540


  44 in total

1.  Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer.

Authors:  Larissa Cramer; Bert Hildebrandt; Thomas Kung; Kristin Wichmann; Jochen Springer; Wolfram Doehner; Anja Sandek; Miroslava Valentova; Tatjana Stojakovic; Hubert Scharnagl; Hanno Riess; Stefan D Anker; Stephan von Haehling
Journal:  J Am Coll Cardiol       Date:  2014-09-30       Impact factor: 24.094

2.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10       Impact factor: 6.875

3.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

4.  Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

Authors:  G Curigliano; D Cardinale; T Suter; G Plataniotis; E de Azambuja; M T Sandri; C Criscitiello; A Goldhirsch; C Cipolla; F Roila
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

5.  Cardiac dysfunction in the trastuzumab clinical trials experience.

Authors:  Andrew Seidman; Clifford Hudis; Mary Kathryn Pierri; Steven Shak; Virginia Paton; Mark Ashby; Maureen Murphy; Stanford J Stewart; Deborah Keefe
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

6.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.

Authors:  G M Felker; R E Thompson; J M Hare; R H Hruban; D E Clemetson; D L Howard; K L Baughman; E K Kasper
Journal:  N Engl J Med       Date:  2000-04-13       Impact factor: 91.245

7.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

8.  Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity.

Authors:  Paulo J Oliveira; James A Bjork; Maria S Santos; Richard L Leino; M Kent Froberg; António J Moreno; Kendall B Wallace
Journal:  Toxicol Appl Pharmacol       Date:  2004-10-15       Impact factor: 4.219

Review 9.  Evaluation and management of patients with heart disease and cancer: cardio-oncology.

Authors:  Joerg Herrmann; Amir Lerman; Nicole P Sandhu; Hector R Villarraga; Sharon L Mulvagh; Manish Kohli
Journal:  Mayo Clin Proc       Date:  2014-09       Impact factor: 7.616

Review 10.  Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.

Authors:  Virginia Shalkey Hahn; Daniel J Lenihan; Bonnie Ky
Journal:  J Am Heart Assoc       Date:  2014-04-22       Impact factor: 5.501

View more
  3 in total

1.  Development and progression of cancer cachexia: Perspectives from bench to bedside.

Authors:  Seongkyun Lim; Jacob L Brown; Tyrone A Washington; Nicholas P Greene
Journal:  Sports Med Health Sci       Date:  2020-12-03

Review 2.  Exercise Counteracts the Deleterious Effects of Cancer Cachexia.

Authors:  Stavroula Tsitkanou; Kevin A Murach; Tyrone A Washington; Nicholas P Greene
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

3.  Physiological monitoring in the complex multi-morbid heart failure patient - Introduction.

Authors:  Giuseppe M C Rosano; Petar M Seferović
Journal:  Eur Heart J Suppl       Date:  2019-12-31       Impact factor: 1.803

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.